Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2020

View Archived Issues

Bayer presents data from the phase II FOXTROT study of osocimab

First-in-human data for NEO-201 in chemoresistant solid tumors

NHP model of Ebola virus infection via mucosal challenge

CureVac and CEPI collaborate to develop vaccine against coronavirus nCoV-2019

Follicum receives grant to study binding of FOL peptides to pancreatic cell receptors

Promising results presented for leronlimab in patients with breast cancer

Vaccitech presents data from the FLU009 phase II study of its VTP-100 vaccine

Adapting NGS for coronavirus surveillance

Long QT genes mostly short on evidence

Immunotherapy combination shows promise in NSCLC

Preclinical data lead to clinical study of in derazantinib in advanced gastric cancer

Exelixis presents phase Ib data for XL-888 plus pembrolizumab in advanced gastrointestinal cancer

Voronoi patents new protein kinase inhibitors

GlaxoSmithKline discloses CREB2 inhibitors

Gilead Sciences describes new IRAK-4 inhibitors

Rodin Therapeutics divulges HDAC inhibitors

Eli Lilly and Company presents SERD inducers for cancer

DB-020 prevents cisplatin-induced hearing loss in animal model, enters clinical trial

Calibr begins first-in-human study of CCW-702 in metastatic castration-resistant prostate cancer

Eisai initiates phase II study of E-7090 in advanced cholangiocarcinoma with FGFR2 gene fusion

Researchers develop an animal model of Marburg virus infection

Gilead provides remdesivir for use in response to novel coronavirus

FDA approves Palforzia oral immunotherapy for peanut allergy

Corvus offers new data from ongoing phase I/Ib trial of CPI-818 in advanced T-cell lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...